The significance of two different free light chain immunoassays for monitoring of disease activity in multiple myeloma patients

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	MAISNAR Vladimír VÁVROVÁ J. MACHÁLKOVÁ K. TICHÝ M. RADOCHA J. FRIEDECKÝ B. HÁJEK Roman PALIČKA V. MALÝ J.
Year of publication	2010
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Description	For most patients with a monoclonal immunoglobulin, measuring FLC is unlikely to have additional benefit for monitoring of disease activity with the notable exception of those with nonsecretory/oligosecretory myeloma. FLCs monitoring could identify patients with resistance to current therapy regimens more quickly than M-Ig determination. Conversely the most rapidly responding patients may have a worse outcome. FLCs measurement can help us also in patients with early relapse still on chemotherapy or in case of free light chains escape phenomenon. Because of the kappa/lambda FLC ratio calculation is strongly influenced by measurement errors, therefore we recommend the preferential use of relevant FLC concentration values.
Related projects:	Vytvoření prognostického panelu u pacientů s monoklonální gamapatií nejasného významu s cílem zabránění transformace v maligní onemocnění